Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus.

CONCLUSIONS: In the first SGLT2i CV outcome trial to evaluate T2DM patients stratified by EF, we found that dapagliflozin reduced HHF in patients with and without HFrEF, and reduced CV death and ACM in patients with HFrEF. CLINICAL TRIAL REGISTRATION: URL: https://clinicaltrials.gov Unique Identifier: NCT01730534. PMID: 30882238 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/30882238?dopt=Abstract

Source: Circulation - March 17, 2019 Category: Cardiology Authors: Kato ET, Silverman MG, Mosenzon O, Zelniker TA, Cahn A, Furtado RHM, Kuder J, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Bonaca MP, Ruff CT, Desai AS, Goto S, Johansson PA, Gause-Nilsson I, Johanson P, Langkilde AM, Raz I, Sabatine MS, Wivio Tags: Circulation Source Type: research